RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].

DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.

RET-IN-23 (compound 17) is a potent, orally active inhibitor of RET, displaying IC50 values of 1.32 nM for RET-WT, 2.50 nM for RET-CCDC6, 6.54 nM for RET-V804L, 1.03 nM for RET-V804M, and 1.47 nM for RET-M918T. The compound demonstrates significant anti-tumor activity [1].

RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximal inhibitory concentrations (IC50s) of 3.6 μM at 3 days and 3.0 μM at 6 days in TT(C634R) MTC [1].

RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].

RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).

RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-V804M. It demonstrates a highly selective inhibition profile across a broad spectrum of kinases, with notable specificity over EGFR and VEGFR2. Additionally, RET-IN-22 is implicated in exerting anticancer effects [1].

RET-IN-20, a potent RET inhibitor, demonstrates an IC50 value of 13.7 nM and effectively decreases the expression of p-Ret and p-Shc protein. Moreover, it induces apoptosis and exhibits antiproliferative and anti-tumor activity.

RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.

RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-channel transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, as well as in the maintenance of homeostasis in the nervous, endocrine, hematopoietic and male reproductive systems. RET-IN-9 has the potential for the study of RET-related diseases, including non-small cell lung cancer and medullary thyroid cancer.

RET-IN-13, a quinoline-based compound, effectively inhibits the RET kinase, demonstrating IC50 values of 0.5 nM for RET (WT) and 0.9 nM for RET (V804M). It holds promise for research into tumors and intestinal diseases associated with abnormal RET activation.

RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.

RET-IN-16 is a potent, selective inhibitor of RET, exhibiting IC50 values of 3.98 nM for RET(WT), 8.42 nM for RET(M918T), 15.05 nM for RET(V804L), 7.86 nM for RET(V804M), 5.43 nM for RET-CCDC6, and 8.86 nM for RET-KIF5B, indicating its high efficacy across different RET mutations. It possesses anticancer properties.

RET-IN-11 is a potent and selective RET inhibitor that acts on RET (IC50: 6.20 nM) and RETV804M (IC50: 18.68 nM).RET-IN-11 induces apoptosis.RET-IN-11 exhibits anti-proliferative and migratory effects in LC-2/ad cells. RET-IN-11 showed anti-proliferative and migratory effects in LC-2/ad cells.

RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).

RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).

RET-IN-14 is a potent inhibitor of RET, capable of acting on RET (WT) (IC50 < 0.51 nM), RET (G810R) (IC50: 9.3 nM), RET (V804M) (IC50: 1.3 nM), BTK (C481S) (IC50: 9.2 nM) and BTK (C481S) (IC50 : 15 nM). RET-IN-14 exhibits potential for tumor studies.

RET-IN-10 is a potent inhibitor of RET, in which RET loss-of-function mutations cause congenital megacolon and its gain-of-function mutations are associated with a variety of human tumors. RET-IN-10 has shown research potential for cancer diseases.

RET-IN-19 is a potent inhibitor of RET and exhibits anticancer effects on RET-wt (IC50: 6.8 nM) and RET V804M (IC50: 13.51 nM).RET-IN-19 can be used to study non-small cell lung cancer (NSCLC).

RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.

RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).

RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).

RET-IN-17 is a potent inhibitor of RET. RET-IN-17 has potential for studies of pain associated with IBS and other gastrointestinal disorders, as well as cancers with constitutive RET kinase activity.

RET-IN-4 is a highly effective and specific RET inhibitor that can be administered orally. It demonstrates remarkable potency, with IC50 values of 1.29 nM, 1.97 nM, and 0.99 nM for inhibiting RET variants including RET (WT), RET (V804M), and RET (M918T), respectively. Moreover, RET-IN-4 exhibits superior selectivity towards kinases JAK2 (IC50 of 4.4 nM) and FLT3 (IC50 of 30.8 nM). Additionally, RET-IN-4 possesses pronounced anticancer properties.

RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice through multiple-day dosing.

Elamipretide (MTP-131) is a mitochondria-targeted antioxidant tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that reduces toxic reactive oxygen species (ROS) production and stabilizes cardiolipin, with blood-brain-barrier permeability. Elamipretide is a potential therapeutic agent in the rare disease of Barnes syndrome.

Combretastatin A4 (CA4) is a microtubule-targeting agent that binds β-tubulin (Kd: 0.4 μM).

Tangeretin (NSC-618905), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models and was also selected as a Notch-1 inhibitor.

BT44 is a novel, second-generation glial cell line_x0002_derived neurotropic factor mimetic with improved biological activity and is a lead compound for the treatment of neurodegenerative disorders.

Isotretinoin (13-cis-Retinoic acid) binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. Isotretinoin is a naturally-occurring retinoic acid with potential antineoplastic activity. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.

Retatrutide sodium salt is a potent triple agonist peptide for glucagon receptor (GCGR), glucose-dependent proinsulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) Retatrutide sodium salt is used in the study of type 2 diabetes and obesity.

Retene (NSC-26317) is widely present in recent and ancient sediments, and compounds can be extracted from fir forest soils, humic coals, terrestrial petroleum hydrocarbon source rocks, and deep-sea sediments.Retene is produced by dehydrogenation of pine acids during petrogenesis.

Methyl 13-cis-4-Oxoretinoate (13-cis-4-Oxo-retinoic acid Methyl Ester) is a retinoic acid metabolite in neuroblastoma.

Methyl retinoate (Retinoic acid, methyl ester) induces aseptic inflammation at the site of administration in in vivo experiments, which causes an increase in the number of leukocytes in the blood and a decrease in the levels of red blood cells and Hb.Methyl retinoate promotes spontaneous leukemia.Methyl retinoate can be Used in the treatment of gastric hypertrophy and ulcers due to vitamin A deficiency. Translated with www.DeepL.com/Translator (free version)

Secretin (33-59), rat (Secretin (rat)) is a classical hormone in the gastrointestinal system and a neuropeptide.

4-Oxofenretinide (3-Keto fenretinide) , a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis.

Demethyldaphnoretin-7-O-glucoside is a natural product that is isolated from Daphne oleoides Schreber subsp. kurdica (DOK). In Turkish traditional medicine, the aerial parts of DOK have been used to treat malaria, rheumatism and for wound healing.

Parethoxycaine hydrochloride (2-(diethylamino)ethyl 4-ethoxybenzoate hydrochloride) is an anesthetic[1].

RETF-4NA acetate is a sensitive, specific substrate for chymotrypsin.

Secretoneurin, rat acetate is a 33-amino acid polypeptide generated by proteolytic processing of secretogranin II (SgII). Secretoneurin, rat acetate induces dopamine release in the rat striatum in vivo and in vitro, and it exerts a very strong chemotactic effect on monocytes and eosinophils but not on granulocytes.

Soretolide (D2916) is a small molecule compound that is used to treat epilepsy.

Methyl-4-oxoretinoate is a synthetic retinoid compound with anticancer compounds that can induce differentiation and apoptosis in cancer cells.Methyl-4-oxoretinoate is used in the treatment of acne, psoriasis, and other skin disorders.Methyl-4-oxoretinoate has the potential to be used in the treatment of a variety of ocular disorders such as age-related macular degeneration. related macular degeneration).

Cathepsin D and E FRET Substrate acetate is a fluorogenic substrate for cathepsins D and E but not for B, H, or L. Cathepsin D and E FRET Substrate acetate can be used in mechanistic studies on cathepsins D and E studies.

γ-Secretase modulator 13 is a γ-secretase modulator (GSMs) that inhibits the production of amyloid β-peptide Aβ42 and can be used to study Alzheimer's disease and tumors.

Ronacaleret HCl (SB-751689) is a small molecule CaSR antagonist for the treatment of endocrine and metabolic diseases, skin and musculoskeletal disorders.

C-Type Natriuretic Peptide (CNP) (1-22), human acetate is an agonist of natriuretic peptide receptor B (NPR-B), an endothelial-derived relaxant and growth inhibitory factor. C-Type Natriuretic Peptide (CNP) (1-22), human acetate inhibits cAMP synthesis stimulated by histamine and 5-HT or directly by Forskolin.

Coretinphencone is a natural product that is isolated from the buds of Coreopsis tinctoria Nutt.

Reticulol is an isocoumarin derivative produced by certain species of Streptomyces. Reticulol inhibits cAMP phosphodiesterase (IC50 = 41 µM). Recticulol (M.W. 222.2) exhibits a potent in vitro cytotoxicity against the human lung tumor cell line A427 and the mouse melanoma cell line B16F10.

gamma-secretase modulator 1 is a modulator of γ secretase and can be used in studies about the treatment of Alzheimer's disease.

Elamipretide TFA (RX-31 TFA) is a cardiolipin peroxidase inhibitor and mitochondria-targeting peptide[1].